Recently, the 2022 China International Fair for Trade in Services ("CIFTIS") was held in Beijing. Sinopharm Group demonstrated to the public the latest scientific and technological achievements of SARS-Cov-2-Vaccine, therapeutic drugs, and diagnostic reagents with the "Technology Anti-epidemic China Plan". Among them, as one of the important activities of Sinopharm Group at the CIFTIS, the DNA Methylation Detection Kit for Human ASTN1、DLX1、ITGA4、RXFP3、SOX17、ZNF671 Gene - Cervical Cancer developed by GeneoDx officially debuted in Beijing. Liu Jingzhen, Chairman of the Sinopharm Group, Yang Liu, Deputy Secretary of the Party Committee of Sinopharm Group, Zhu Jingjin, Secretary of the Party Committee of Sinopharm, and other leaders and experts attended the press conference.
The reporter learned that this product has obtained the medical device registration certificate issued by the National Medical Products Administration, which is the first certificate for HPV methylation shunt in the primary screening of cervical cancer in China.
Chen Kun, General Counsel of CNBG presided over the meeting
Speech by Zhang Yuntao, Chief Scientist and Vice President of Sinopharm CNBG
Zhang Yuntao, Chief Scientist and Vice President of Sinopharm CNBG, pointed out in a speech at the press conference that CNBG has always adhered to the corporate values of "love and responsibility" in its more than 100 years’ struggle. The successful approval of the kit is a vivid practice of CNBG’s philosophy “All for health, health for all” by science and technology innovation. It is a positive action of practicing the Healthy China strategy and building a Global Community of Health for All, striving to contribute more strength and wisdom to the health and well-being of billions of Chinese people.
Cao Zeyi, former Vice Minister of the Ministry of Health and former Chairman of the Obstetrics and Gynecology Branch of Chinese Medical Association, delivered a speech
Cao Zeyi, former Vice Minister of the Ministry of Health and former Chairman of the Obstetrics and Gynecology Branch of Chinese Medical Association, said in his speech that China has made great progress in cervical cancer screening over the years, but some clinical problems have not been resolved yet. For example, if HPV result is positive and cervical lesions occur, it may continue to develop into cancer or subside within a certain period of time. If it cannot be distinguished accurately and scientifically, over-diagnosis and overtreatment may occur, which will bring a burden to patients. Cervical cancer methylation detection technology can effectively solve this problem. It is hoped that this technology can assist the cervical cancer screening project in China and provide a more scientific basis for follow-up processing of cervical cancer screening.
Wei Lihui, Honorary Director of the Department of Obstetrics and Gynecology of Peking University People's Hospital and Vice President of the Obstetrics and Gynecology Branch of Chinese Medical Doctor Association, delivered a keynote speech
Hong Ying, Director of Obstetrics and Gynecology at Nanjing Drum Tower Hospital and Vice Director of Reproductive Tract Infection Professional Committee of Maternal and Child Health Research Association, delivered a keynote speech
At the meeting, Wei Lihui, Honorary Director of the Department of Obstetrics and Gynecology of Peking University People's Hospital and Vice President of the Obstetrics and Gynecology Branch of Chinese Medical Doctor Association; Hong Ying, Director of Obstetrics and Gynecology at Nanjing Drum Tower Hospital and Vice Director of Reproductive Tract Infection Professional Committee of Maternal and Child Health Research Association delivered keynote speeches respectively.
Cervical cancer is one of the most common gynecological malignancies, which has seriously threatened women's health for a long time. Early screening and detection of precancerous lesions and active treatment are important means of preventing cervical cancer.
It is understood that the kit uses a methylation-specific PCR method to detect the methylation status of 6 specific human genes, helping to identify whether the HPV test-positive population needs further colposcopy examination. The kit can perform cervical cancer screening and diversion more accurately and efficiently: if the test result of the kit is negative, it indicates that there is no cervical lesion or the grade of cervical lesion is low, which can avoid colposcopy and tissue biopsy examination. Regular follow-up is sufficient; if the test result is positive, it indicates a high-grade cervical lesion, and further colposcopy examination and/or tissue biopsy examination are required.
Transient infection and regression rates are high among HPV-infected populations, experts said. The kit can effectively distinguish which patients with HPV infection have a higher risk of cancer and which patients are more likely to be transiently infected. This is of great significance for the optimization of the entire cervical cancer screening strategy, for reducing the anxiety of patients, and for saving medical resources.
According to estimates, the application of this product can reduce more than 60% of unnecessary colposcopy referrals for the related patients (about 40 million Chinese women) so as to avoid waste of medical resources.
Since July 2009, China has launched the "Two Cancers" Screening Project for cervical cancer and breast cancer, benefiting hundreds of millions of women of appropriate age. In January 2022, the screening target was further expanded from age-appropriate rural women to age-appropriate urban and rural women. The approval of the GeneoDx cervical cancer methylation kit will further optimize Chinese cervical cancer screening strategy, effectively promote the realization of the four early stages of cervical cancer "early prevention, early detection, early diagnosis, and early treatment", and protect women's health .
According to reports, Shanghai GeneoDx Biotech Co., Ltd. (GeneoDx) is a subsidiary of China National Biotec Group Company Limited (CNBG), China National Pharmaceutical Group Co., Ltd. (Sinopharm), and its products focus on multiple detection of infectious disease pathogens and molecular diagnosis of tumors. In early 2020, GeneoDx successfully developed COVID-19 nucleic acid detection kit, obtained the first batch of medical device registration certificate issued by the National Medical Products Administration, passed the CE certification, and was included in the World Health Organization (WHO) Emergency Use Listing. GeneoDx has always taken "All for health ,health for all" as its corporate philosophy, and has played an active role in promoting people's health and industry development.